Companies PMV Pharmaceuticals, Inc.
PMV Pharmaceuticals (PMVP): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Email me PMV Pharmaceuticals, Inc.’s executive pay brief as a PDF
It arrives in about 2 minutes, with every figure cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $2,209,795FY2023
- $4,760,281FY2024
- $1,665,191FY2025
CEO total pay was $1,665,191 in fiscal 2025, down from $4,760,281 in fiscal 2024.
FY2025: salary $628,461 · bonus $0 · stock awards $0 · option awards $752,320
Order PMVP
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| David Mack | $628,461 | $0 | $0 | $752,320 | $284,410 | $0 | $0 | $1,665,191 |
| President, Chief Executive Officer and Director | ||||||||
| Pharm.D. Deepika Jalota | 478,429 | 0 | — | 282,120 | 174,638 | 0 | 0 | 935,187 |
| Chief Development Officer | ||||||||
| Robert Ticktin | 450,000 | 0 | 0 | 249,206 | 162,000 | 0 | 0 | 861,206 |
| General Counsel & Chief Operating Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| David Mack | $1,665,191 | $4,760,281 | $2,209,795 | ↓ −3,095,090 |
| Pharm.D. Deepika Jalota | 935,187 | 1,929,014 | — | ↓ −993,827 |
| Robert Ticktin | 861,206 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The company's compensation program is designed to attract, motivate, and retain talented executives by providing competitive base salaries and annual bonuses tied to the achievement of development, pipeline, and corporate goals, as well as long-term equity incentives to align executive interests with shareholders.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pearl Meyer & Partners, LLC |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| David Mack | OPTION | 2025-03-03 | — | — | 800,000 | — | $752,320 |
| Carol Gallagher, Pharm.D | OPTION | 2025-03-03 | — | — | 300,000 | — | 282,120 |
| Robert Ticktin | OPTION | 2025-03-03 | — | — | 265,000 | — | 249,206 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| David Mack | $0 | $0 | $752,320 | 0.0% |
| Carol Gallagher, Pharm.D | 0 | 0 | 282,120 | 0.0% |
| Robert Ticktin | 0 | 0 | 249,206 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Pharm.D. Deepika Jalota | Option | 50,429 | 1.48 | — |
| Robert Ticktin | Option | 57,988 | 1.48 | — |
| Robert Ticktin | Option | 61,334 | 1.48 | — |
| Pharm.D. Deepika Jalota | Option | 83,335 | 1.48 | — |
| Robert Ticktin | Option | 87,928 | 1.8 | — |
| Pharm.D. Deepika Jalota | Option | 117,238 | 1.8 | — |
| David Mack | Option | 213,433 | 1.48 | — |
| Robert Ticktin | Option | 215,313 | 1.32 | — |
| David Mack | Option | 220,001 | 1.48 | — |
| Pharm.D. Deepika Jalota | Option | 243,750 | 1.32 | — |
| David Mack | Option | 270,790 | 1.8 | — |
| David Mack | Option | 650,000 | 1.32 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Charles M. Baum, M.D., Ph.DIndependent · Compensation · Nominating and Corporate Governance (Chair) | $53,000 | $0 | $21,691 | $0 | $100,000 | $174,691 |
| Arnold Levine, Ph.DIndependent | 40,000 | 0 | 21,691 | 0 | 100,000 | 161,691 |
| Richard Heyman, Ph.DIndependent · Board Chair · Audit · Compensation (Chair) · Nominating and Corporate Governance | 96,500 | 0 | 21,691 | 0 | 0 | 118,191 |
| Laurie StelzerIndependent · Audit (Chair) · Compensation | 60,000 | 0 | 21,691 | 0 | 0 | 81,691 |
| Kirsten FlowersIndependent · Audit | 47,500 | 0 | 21,691 | 0 | 0 | 69,191 |
| Carol Gallagher, Pharm.DIndependent · Nominating and Corporate Governance | 44,000 | 0 | 21,691 | 0 | 0 | 65,691 |
| David H. Mack, Ph.DEmployee director | — | — | — | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 10,000 / 8,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $341,000 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $200,000 |
| Total cost of the board | $541,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names PMV Pharmaceuticals as a peer
Companies that benchmark against PMVP
3 companies name PMVP as a compensation peer
- KYNTRA BIO, INC.FGENFY2025
- Repare Therapeutics Inc.RPTXFY2024
- Shattuck Labs, Inc.STTKFY2025
Each company listed discloses PMVP in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named PMVP in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | PMV Pharmaceuticals, Inc. | 2025 | David Mack | $628,461 | $0 | $752,320 | $284,410 | $1,665,191 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
No say-on-pay vote is on file for this company.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (17 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, David Mack. DEF 14A, filed 2026-04-22. Section “Summary Compensation Table” · page 20. As printed: 1,665,191. View filing ↗
- Section 01, Pharm.D. Deepika Jalota. DEF 14A, filed 2026-04-22. Section “Summary Compensation Table” · page 20. As printed: 935,187. View filing ↗
- Section 01, Robert Ticktin. DEF 14A, filed 2026-04-22. Section “Summary Compensation Table” · page 20. As printed: 861,206. View filing ↗
- Section 03, David Mack OPTION. DEF 14A, filed 2026-04-22. Section “Grants of Plan-Based Awards for Fiscal 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Carol Gallagher, Pharm.D OPTION. DEF 14A, filed 2026-04-22. Section “Grants of Plan-Based Awards for Fiscal 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Robert Ticktin OPTION. DEF 14A, filed 2026-04-22. Section “Grants of Plan-Based Awards for Fiscal 2025” · grants of plan-based awards table. View filing ↗
- Section 08, Charles M. Baum, M.D., Ph.D. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 174,691. View filing ↗
- Section 08, Arnold Levine, Ph.D. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 161,691. View filing ↗
- Section 08, Richard Heyman, Ph.D. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 118,191. View filing ↗
- Section 08, Laurie Stelzer. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 81,691. View filing ↗
- Section 08, Kirsten Flowers. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 69,191. View filing ↗
- Section 08, Carol Gallagher, Pharm.D. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 65,691. View filing ↗
- Section 08, David H. Mack, Ph.D. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 341,000 + equity 0 + all other 200,000 = 541,000, summed across the director compensation table rows.
- PMV Pharmaceuticals, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in PMV Pharmaceuticals, Inc.'s own proxy. As printed: 1,665,191. View filing ↗